For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs) do not consistently influence risk ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...

One benefit of GC/Chlamydia testing at the initial visit is avoidance of future visits. However, if the cost of an office visit is low, or undiagnosable patients get better without treatment ...

Trichomoniasis is the most common non-viral STI in the United States, affecting women four times more often than men. An estimated 1 million new trichomoniasis infections occur each year. Caused by ...

Early treatment can help prevent complications ... It may also be easy to mistake STI symptoms for those of another issue. Chlamydia is a bacterial STI that passes from person to person through ...

Doxycycline discharge kits significantly improve guideline-directed treatment and reduce time to definitive treatment in patients with chlamydia who were discharged from the emergency department (ED).

Joe Mangy undergoing a check up a week into his treatment On a species level though, the disease, which spreads through bodily fluids, causes even greater ruin. Chlamydia is not uncommon in other ...

While there’s no cure for autism, there are many approaches that can help both children and adults manage their symptoms and improve their quality of life. Autism spectrum disorder is a ...

Increasing AMR in NG, considerable variability in the treatment regimens recommended by PHAC and other guideline development groups, and increasing rates of gonococcal infection prompted the NAC-STBBI ...

Chronic lymphocytic leukemia (CCL) can affect each person differently. Current treatment options range from conservative monitoring to advanced drug therapies and novel agents under review in ...